Brief: Vaxart Announces Last Subject Dosed In Phase 1 Trial Of Its Norovirus Vaccine Candidate In Lactating Mothers
21/12/2023 13:40
Dec 21 (Reuters) - Vaxart Inc VXRT.O :
* VAXART ANNOUNCES LAST SUBJECT DOSED IN PHASE 1 TRIAL OF
ITS
NOROVIRUS VACCINE CANDIDATE IN LACTATING MOTHERS
* VAXART INC: ON TRACK TO REPORT TOPLINE DATA BY END OF 2024
Source text for Eikon: ID:nGNX7wJmzR
Further company coverage: VXRT.O
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts